{"id":14066,"date":"2019-09-19T09:02:42","date_gmt":"2019-09-19T13:02:42","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14066"},"modified":"2019-09-19T09:02:42","modified_gmt":"2019-09-19T13:02:42","slug":"inspector-general-part-d-rebates-grew-but-not-enough-to-offset-drug-price-hikes","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14066","title":{"rendered":"Inspector general: Part D rebates grew, but not enough to offset drug price hikes"},"content":{"rendered":"<p>(By Maia Anderson for Becker&#8217;s Hospital Review)<\/p>\n<p>Although rebates for brand-name drugs in Medicare Part D substantially reduced drug spending, the rebates were not enough to offset major spikes in drug prices, according to a new\u00a0study\u00a0from Office of Inspector General cited by\u00a0STAT.\u00a0 Continue reading article <a href=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/inspector-general-part-d-rebates-grew-but-not-enough-to-offset-drug-price-hikes.html\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-9962\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General-300x74.jpg\" alt=\"\" width=\"300\" height=\"74\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General-300x74.jpg 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2018\/03\/DHS-Office-of-Inspector-General.jpg 623w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Maia Anderson for Becker&#8217;s Hospital Review) Although rebates for brand-name drugs in Medicare Part D substantially reduced drug spending,<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-14066","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14066"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14066\/revisions"}],"predecessor-version":[{"id":14067,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14066\/revisions\/14067"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}